OKLAHOMA CITY, OK--(Marketwired - July 29, 2015) - Cytovance® Biologics, Inc., a leading full-service contract development and manufacturer of mammalian and microbial biologics, announces that it has teamed up with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions.
"Stem cells have demonstrated promise in early clinical trials evaluating safety, feasibility, and effectiveness for treating stroke. The mechanism of action by which multipotent adult stem cells address the complex pathophysiology of stroke is not predominantly their ability to differentiate into cell types that replace tissues lost to injury, but occurs through soluble therapeutic factors secreted by these cells which promote survival and repair," says Wade Lange, M.S. (NeuroFx CEO). Brian Johnstone Ph.D., (NeuroFx Director of R & D), states, "Recognition of the critical function of mesenchymal stem cells' (MSC) paracrine factors has prompted investigation into many different disease models of conditioned medium (CM) obtained from culturing MSC. Studies in rodent stroke models have validated the therapeutic potential of adipose stem/stromal cell (ASC) as well as MSC-derived therapeutic factors, demonstrating a similar effect as with cell delivery."
NeuroFx has selected Cytovance Biologics Inc. (Oklahoma City, OK) to team up to develop a therapeutic factor concentrate Platform and Program to deliver a robust development and manufacturing process. John Conner (Cytovance Biologics Vice President of Manufacturing Operations) states, "We are excited to work together with NeuroFx to develop and manufacture a cell free therapeutic for neurological conditions based on a MSC-CM platform."
Cytovance® Biologics is a biopharmaceutical contract development manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Learn more about Cytovance Biologics at www.cytovance.com
NeuroFx is an Indiana-based regenerative medicine company that is developing an innovative, cell-free Therapeutic Factor Concentrate (TFC) derived from adult adipose (fat) stem cells. TFC is an off-the-shelf, ready-to-use product that harnesses the healing potential of adult stem cells while addressing therapeutic and practical shortcomings of stem cell therapies. The scientific founders of the company, Drs. Keith March, MD, PhD, and Yansheng Du, PhD of the Indiana University School of Medicine, developed the NeuroFx core technology.
Learn more about NeuroFx at neurofx.co